Our DNA
Building Transformational Therapy
Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.
Vivet is building a diversified gene therapy pipeline based on novel recombinant adeno-associated virus (rAAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain.
Vivet is currently working on the following programs:
VTX-PID
Vivet is working on advancing innovative technology platforms to expand patient accessibility to gene therapy.
Our clinical asset, VTX-PID, directly tackles the challenge of pre-existing humoral immune responses to AAV viral vectors, a major barrier preventing many patients from accessing gene therapy.
VTX-PID utilizes an IgG-degrading enzyme, derived from Streptococcus pyogenes, designed to transiently remove all human IgG subclasses.
This breakthrough approach enables temporary evasion of host humoral immune defenses, allowing more patients, including those with neutralizing antibodies, to benefit from transformative viral vector-based therapies.
Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer Inc., Columbus Venture Partners, Ysios Capital, Kurma Partners and Eurazeo.
Vivet Therapeutics is developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders
Disruptive development engine
Collaboration with the Fundacio Para La Investigation Medica Aplicada (FIMA)
VTX-806
Cerebrotendinous xanthomatosis (CTX) is an ultra-rare, progressive neurodegenerative disorder caused by mutations in the CYP27A1 gene, leading to severe disruption of cholesterol metabolism and bile acid synthesis. Patients with CTX face substantial unmet medical needs, with limited therapies available to halt disease progression notably neurological deterioration.
Vivet’s VTX-806 program, an innovative rAAV gene therapy, aims to directly address these unmet needs by delivering a functional CYP27A1 gene to restore mitochondrial sterol 27-hydroxylase activity, potentially transforming the management of CTX. VTX-806 has received Orphan Drug Designation both in Europe and the US, underscoring its promise for this underserved patient population. VTX-806 has also received FDA preIND feedback supporting its non-clinical and clinical design strategy. The program’s development is supported by the French Government under the France Health Innovation Plan 2030, operated by Bpifrance.
VTX-801
VTX-801, Vivet’s investigational gene therapy for Wilson’s Disease (WD), has received Orphan Drug and Fast Track designations from both the FDA and the EC.
The WD Gateway trial has stopped recruitment and is now focused exclusively on long-term follow-up of already treated patients, with five years of monitoring planned.
Data from this trial will be published as further results become available.
